Cyclacel Pharmaceuticals, Inc.
CYCC
$0.269
-$0.0102-3.65%
| Weiss Ratings | CYCC - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Rating | ||||
| Reward Index | Very Weak | |||
| Risk Index | Very Weak | |||
| Risk Grade | E+ | |||
| Reward Grade | E | |||
| Rating Factors | CYCC - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Dividend Index | -- | |||
| Growth Index | Fair | |||
| Efficiency Index | Very Weak | |||
| Solvency Index | Fair | |||
| Total Return Index | Very Weak | |||
| Volatility Index | Very Weak | |||
| Beta / Standard Deviation | CYCC - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Beta | 0.08 | |||
| Price History | CYCC - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| 7-Day Total Return | -10.21% | |||
| 30-Day Total Return | -27.63% | |||
| 60-Day Total Return | -28.46% | |||
| 90-Day Total Return | -28.07% | |||
| Year to Date Total Return | -27.47% | |||
| 1-Year Total Return | -86.88% | |||
| 2-Year Total Return | -96.85% | |||
| 3-Year Total Return | -99.44% | |||
| 5-Year Total Return | -99.76% | |||
| 52-Week High % Change | -92.52% | |||
| 52-Week Low % Change | 2.86% | |||
| Price | CYCC - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| 52-Week High Price | $4.00 | |||
| 52-Week Low Price | $0.29 | |||
| 52-Week Low Price (Date) | Mar 18, 2025 | |||
| 52-Week High Price (Date) | May 01, 2024 | |||
| Valuation | CYCC - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Market Cap | 73.66M | |||
| Enterprise Value | 70.68M | |||
| Price/Earnings (TTM) | -- | |||
| Earnings Per Share (TTM) | -11.21 | |||
| Earnings Per Share Growth | -62.27% | |||
| Price/Earnings To Growth | -- | |||
| Price/Sales (TTM) | 8.72 | |||
| Price/Book (Q) | -0.66 | |||
| Enterprise Value/Revenue (TTM) | 955.12 | |||
| Price | $0.27 | |||
| Enterprise Value/EBITDA (TTM) | -4.55 | |||
| Enterprise Value/EBIT | -4.55 | |||
| Market Cap Category | Micro Cap | |||
| Dividends and Shares | CYCC - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Shares Outstanding | 2.15M | |||
| Dividend Yield | -- | |||
| Div. Per Share (Most Recent) | -- | |||
| Dividend Per Share (TTM) | -- | |||
| Payout Ratio (TTM) | -0.37% | |||
| Dividend Per Share (Most Recent) | -- | |||
| Company Info | CYCC - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Phone Number | 908 517 7330 | |||
| Address | 200 Connell Drive Berkeley Heights, NJ 07922 | |||
| Website | www.cyclacel.com | |||
| Country | United States | |||
| Year Founded | 1996 | |||
| Profitability | CYCC - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Operating Margin (TTM) | -20,994.59% | |||
| Profit Margin | -18,150.00% | |||
| Management Effectiveness | CYCC - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Return on Assets | -108.63% | |||
| Return on Equity | -- | |||
| Income Statement | CYCC - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Revenue (TTM) | 74.00K | |||
| Total Revenue (TTM) | 74.00K | |||
| Revenue Per Share | $0.03 | |||
| Gross Profit (TTM) | 74.00K | |||
| EBITDA (TTM) | -15.52M | |||
| EBIT (TTM) | -15.54M | |||
| Net Income (TTM) | -13.43M | |||
| Net Income Avl. to Common (TTM) | -13.48M | |||
| Total Revenue Growth (Q YOY) | -37.50% | |||
| Earnings Growth (Q YOY) | 67.56% | |||
| EPS Diluted (TTM) | -11.21 | |||
| EPS Diluted Growth (Q YOY) | 87.40% | |||
| Balance Sheet | CYCC - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Cash and Short-Term Inv. (Q) | 2.98M | |||
| Cash Per Share (Q) | $1.39 | |||
| Total Current Assets (Q) | 4.91M | |||
| Total Preferred Equity (Q) | -- | |||
| Total Equity (Q) | -970.00K | |||
| Current Ratio (Q) | 0.774 | |||
| Book Value Per Share (Q) | -$0.45 | |||
| Total Assets (Q) | 5.38M | |||
| Total Current Liabilities (Q) | 6.35M | |||
| Total Debt (Q) | 0.00 | |||
| Total Liabilities (Q) | 6.35M | |||
| Total Common Equity (Q) | -970.00K | |||
| Cash Flow | CYCC - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Cash from Investing (TTM) | 0.00 | |||
| Cash from Financing (TTM) | 7.21M | |||
| Net Change in Cash (TTM) | -2.96M | |||
| Levered Free Cash Flow (TTM) | -7.45M | |||
| Cash from Operations (TTM) | -10.54M | |||
